Dr. Gary Shienbaum, MD

Dr. Shienbaum practices at Retina Group Of Florida in Fort Lauderdale, Florida.

Dr. Shienbaum's NPI, 1770781502, was assigned on July 3, 2007. Dr. Shienbaum graduated from Sidney Kimmel Medical College in 2007. Dr. Shienbaum holds Florida license ME109057.

Dr. Shienbaum's primary practice is Retina Group of Florida, at 6333 N Federal Hwy Ste 300 Suite 300, Fort Lauderdale, FL 33308. The practice phone is (954) 776-6880.

Dr. Shienbaum's primary practice is Retina Group Of Florida in Fort Lauderdale, Florida. Dr. Shienbaum is also affiliated with Broward Health Imperial Point. Dmand AI also links Dr. Shienbaum to 1 more hospital, 3 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shienbaum practices, 4 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Shienbaum's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Shienbaum is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Shienbaum's licenses on file in 2 states: Florida and Pennsylvania.

Dmand AI lists age-related macular degeneration, cataract, conjunctivitis, eyelid inflammation, glaucoma, hypertensive retinopathy, inflammation of iris and laser destruction of retinal or choroid lesions among the conditions Dr. Shienbaum treats.

CMS data shows 20,841 Medicare services from Dr. Shienbaum across 13 procedure codes in 2024, for 413 Medicare patients. Medicare paid $700,776 for them. Every service was in an office.

CMS counts 413 Medicare patients who saw Dr. Shienbaum in 2024. The largest group is 65 to 74, with 199 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.42, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Shienbaum's median patient age at 71, with 51% women.

In 2024, Dr. Shienbaum wrote 888 Medicare Part D claims for 218 patients. 48% of them were for generic drugs. CMS names the drug for 783 of them, across 15 drugs with 11 or more claims each, at $583,634 in total drug cost. In 2023, CMS named 637 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Shienbaum for performance year 2024, reported individually. Dr. Shienbaum accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 9 papers to Dr. Shienbaum, published from 2010 to 2013. The most frequent topics are Visual Acuity, Angiogenesis Inhibitors and Antibodies, Monoclonal, Humanized. Dr. Shienbaum has published most often in Am J Ophthalmol. Dr. Shienbaum's most frequent co-authors are Harry W. Flynn, MD, Richard S. Kaiser, MD and William E. Smiddy, MD.

Dmand AI links Dr. Shienbaum to 4 clinical trials. Conditions studied include Vitreous Detachment and Eye Diseases. Regeneron Pharmaceuticals sponsors the most, 2. Open Payments lists research payments to Dr. Shienbaum that name 2 trials.

CMS Open Payments shows 148 general payments to Dr. Shienbaum from 22 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 67% of the total. Alimera Sciences, Inc. paid the most, $16,042. It also lists 9 research payments totaling $1,559 from 2016 to 2017, naming 2 clinical trials.

Dr. Shienbaum graduated from Sidney Kimmel Medical College in 2007.

Dr. Shienbaum is in network with 18 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 12. Check the plan with the practice before a visit.